Search

Your search keyword '"Parving, H. H."' showing total 71 results

Search Constraints

Start Over You searched for: Author "Parving, H. H." Remove constraint Author: "Parving, H. H." Publisher springer verlag Remove constraint Publisher: springer verlag
71 results on '"Parving, H. H."'

Search Results

1. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.

2. SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.

3. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study.

4. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

5. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

6. A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.

7. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes.

8. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.

9. Telomere length predicts all-cause mortality in patients with type 1 diabetes.

10. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

11. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.

12. Long-term prevention of diabetic nephropathy: an audit.

13. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control.

14. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.

15. Anaemia in diabetes: Is there a rationale to TREAT?

16. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients.

17. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

18. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications.

20. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.

21. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

22. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

23. Total plasma homocysteine is associated with hypertension in Type I diabetic patients.

24. Controlling hypertension in diabetes.

25. Pregnancy and progression of diabetic nephropathy.

26. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients.

27. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy.

28. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.

29. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy.

30. Glomerular hyperfiltration in microalbuminuric NIDDM patients.

31. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.

32. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

33. Monitoring kidney function in diabetic nephropathy.

34. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.

35. Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.

36. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.

37. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients.

38. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

39. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.

40. Lack of familial predisposition to cardiovascular disease in type 1 (insulin-dependent) diabetic patients with nephropathy.

41. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance.

43. Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy.

44. The effect of glucagon infusion on kidney function in short-term insulin-dependent juvenile diabetics.

45. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics.

46. The effect of intravenous insulin infusion on kidney function in insulin-dependent diabetes mellitus.

47. Diabetic nephropathy and arterial hypertension.

48. Effect of metabolic regulation on renal leakiness to dextran molecules in short-term insulin-dependent diabetics.

49. Decreased distensibility of a passive vascular bed in diabetes mellitus: an indicator of microangiopathy?

50. Haemodynamic changes during graded exercise in patients with diabetic autonomic neuropathy.

Catalog

Books, media, physical & digital resources